Facebook Twitter Instagram
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Facebook Twitter Instagram
    Pharmacognosy Communications
    • Home
    • About Journal
      • Aim and Scope
      • Editorial Board
      • Indexing Info
      • Contact Us
    • Browse Issues
      • Articles in Press
      • Current Issue
      • Past Issues
    • For Authors
      • Instructions to Authors
      • Article Processing Charges
      • Submit your article
      • Downloads
    Pharmacognosy Communications
    retyeyutreu
    Original Article

    Tasmannia lanceolata (Poir.) A.C.Sm. Berry and Leaf Extracts Inhibit Proliferation and Induce Apoptosis in Selected Human Carcinoma Cell Lines

    Web AdminBy Web AdminJuly 20, 2023Updated:September 7, 2023No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Share
    Facebook Twitter LinkedIn WhatsApp Pinterest Email

    Joseph Shalom1,2, Ian Edwin Cock1,2,*

    1Centre for Planetary Health and Food Security, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland, AUSTRALIA.

    2School of Science and Environment, Nathan Campus, Griffith University, 170 Kessels Rd, Nathan, Queensland, AUSTRALIA.

    DOI: 10.5530/pc.2023.3.20

    ABSTRACT

    Background: Tasmannia lanceolata berries and leaves have high antioxidant capacities and high levels of therapeutic phytochemicals. Despite this, the anticancer activity of T. lanceolata extracts has not been adequately explored. Materials and Methods: This study examined the anti-proliferative of T. lanceolata berry and leaf extracts against a panel of human carcinoma cell lines using MTS assays. The apoptotic activities were examined using cell imaging and caspase-3 activity assays. LC-MS and GC-MS headspace analysis were used to identify noteworthy phytochemical components. Results: The methanolic, aqueous and ethyl acetate extracts inhibited the proliferation of HeLa, Caco-2, Jeg-3, JAR, MC3T3-E1 and MG63 cell lines. The aqueous leaf extract was a particularly potent inhibitor of proliferation against most cell lines (HeLa IC50 = 230μg/mL; Caco-2 IC50 = 150μg/mL; Jeg-3 IC50 = 488μg/mL; JAR IC50 = 450μg/mL; MC3T3 IC50 = 195μg/mL; MG63 IC50 = 315μg/mL). The berry and leaf ethyl acetate extracts were also good inhibitors of proliferation of the same cell lines, albeit with slightly higher IC50 values. Morphological features consistent with apoptosis were evident in Caco-2 cells exposed to the berry and leaf ethyl acetate extracts, and the aqueous leaf extract. Furthermore, exposure of Caco-2 to sub-lethal concentrations of these extracts induced significantly elevated levels of caspase 3, indicating that the extracts induced apoptosis in Caco-2 cells. Conclusion: All T. lanceolata berry and leaf extracts induced apoptosis in a panel of cancer cells and were nontoxic in the ALA toxicity bioassay and in a HDF cell viability assay, supporting their potential as cancer chemotherapies.

    Keywords: Winteraceae, Tasmanian pepper, Mountain pepperberry, Anti-cancer activity, Anti-proliferative activity, Antioxidant capacity, Apoptosis.

    Download PDF
    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    About Journal
    About Journal

    Pharmacognosy Communications [Phcog Commn.] is a quarterly journal published by Phcog.Net. It is a peer reviewed journal aiming to publish high quality original research articles, methods, techniques and evaluation reports, critical reviews, short communications, commentaries and editorials of all aspects of medicinal plant research. The journal is aimed at a broad readership, publishing articles on all aspects of pharmacognosy, and related fields. The journal aims to increase understanding of pharmacognosy as well as to direct and foster further research through the dissemination of scientific information by the publication of manuscripts. The submission of original contributions in all areas of pharmacognosy are welcome.
    Indexed and Abstracted in : Chemical Abstracts, Excerpta Medica / EMBASE, Google Scholar, CABI Full Text, Ulrich’s International Periodical Directory, ProQuest, Journalseek & Genamics, PhcogBase, EBSCOHost, Academic Search Complete, Open J-Gate, SciACCESS.
    Rapid publication: Average time from submission to first decision is 30 days and from acceptance to In Press online publication is 45 days.
    Open Access Journal: Phcog Commn. is an open access journal, which allows authors to fund their article to be open access from publication.

    © 2025 Pharmacognosy Communications. Maintained by Manuscript TechnoMedia LLP.

    Type above and press Enter to search. Press Esc to cancel.

    Scroll Up